We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blood Platelet Score Detects Previously Unmeasured Risk of Heart Attack and Stroke

By LabMedica International staff writers
Posted on 22 Aug 2024
Print article
Image: The new platelet-centric scoring system predicts platelet hyperreactivity and related risk of cardiovascular events (Photo courtesy of Shutterstock)
Image: The new platelet-centric scoring system predicts platelet hyperreactivity and related risk of cardiovascular events (Photo courtesy of Shutterstock)

Platelets, which are cell fragments circulating in the blood, play a critical role in clot formation to stop bleeding. However, in some individuals, platelets can become "hyperreactive," leading to excessive clotting and causing heart attacks, strokes, and peripheral artery disease, affecting millions worldwide. Until now, assessing platelet reactivity in patients has been challenging due to inconsistencies in the conventional test, platelet aggregometry, which often shows varied results across different laboratories. To overcome this issue, researchers have now accurately identified patients with hyperreactive platelets and conducted a study revealing significant genetic variations among those with hyperreactive platelets compared to others. Using bioinformatics, they developed a new metric called the Platelet Reactivity ExpresSion Score (PRESS), which effectively identifies those at risk of heart attacks and spots those who might not yet know their risk.

Researchers at NYU Grossman School of Medicine (New York, NY, USA) designed PRESS by switching to a low-dose epinephrine aggregometry technique, which is more indicative of hyperreactivity than previous high-dose tests. This method determined hyperreactive platelets based on their reaction to a minimal stimulus. To move beyond the confines of specialized laboratory techniques, the team developed PRESS as a standardizable, genetic-based score to predict cardiovascular risk. This tool was designed to be broadly applicable, avoiding the variability of direct platelet testing.

The researchers validated the clinical relevance of PRESS in a study tracking major adverse cardiovascular events in patients undergoing procedures to clear blocked arteries. Upon comparing PRESS to traditional aggregometry results and examining its diagnostic ability in various patient populations, they found that higher PRESS scores correlated with increased cardiovascular events. The findings, published online on August 20 in Nature Communications, found that those identified as having hyperreactive platelets faced a significantly higher risk of serious cardiovascular events shortly after surgery, providing a new tool for early identification and management of patients at risk due to platelet hyperreactivity.

"Our results demonstrate that our new platelet-centric scoring system can, for the first time and across populations, circumvent aggregometry to reliably predict platelet hyperreactivity and the related risk of cardiovascular events," said corresponding study author Jeffrey Berger, MD, director of the Center for the Prevention of Cardiovascular Disease at NYU Grossman School of Medicine.

"In current practice, anti-platelet therapy is not routinely recommended for the prevention of a first heart attack or stroke, but a platelet-based test would help to identify patients at highest risk, and those who would benefit most from anti-platelet therapy to prevent a cardiovascular event," added study author Tessa Barrett, PhD, assistant professor in the departments of Medicine and Pathology at NYU Langone. "Our score has the potential to further personalize cardiovascular disease risk prevention."

Related Links:
NYU Grossman School of Medicine

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Centromere B Assay
Centromere B Test
New
Silver Member
ACTH Assay
ACTH ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.